WFG Advisors’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

WFG Advisors’s Portfolio PBE Stock Details PBE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	$21K	Hold	450	–	–	﹤0.01%	949
2017 Q1	$19K	Hold	450	–	–	0.01%	898
2016 Q4	$17K	Hold	450	–	–	﹤0.01%	975
2016 Q3	$19K	Sell	450 -75	-14%	-$3.08K	﹤0.01%	958
2016 Q2	$19K	Hold	525	–	–	0.01%	930
2016 Q1	$20K	Hold	525	–	–	0.01%	894
2015 Q4	$27K	Sell	525 -189	-26%	-$9.34K	0.01%	824
2015 Q3	$33K	Hold	714	–	–	0.01%	762
2015 Q2	$42K	Hold	714	–	–	0.01%	775
2015 Q1	$39K	Sell	714 -221	-24%	-$11.9K	0.01%	797
2014 Q4	$47K	Buy	935 +10	+1%	+$489	0.01%	911
2014 Q3	$43K	Sell	925 -1,675	-64%	-$75.5K	0.01%	985
2014 Q2	$114K	Sell	2,600 -28,997	-92%	-$1.17M	0.02%	613
2014 Q1	$1.31M	Buy	31,597 +335	+1%	+$14.3K	0.26%	78
2013 Q4	$1.16M	Buy	31,262 +4,864	+18%	+$174K	0.16%	146
2013 Q3	$926K	Buy	26,398 +25,148	+2,012%	+$833K	0.14%	168
2013 Q2	$36K	Buy	+1,250	New	+$35.5K	0.01%	1011

Other funds holding PBE

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

SAM

SignalPoint Asset Management Springfield, Missouri $411M AUM 23.81% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

CAS

Cue Advisory Services Phoenix, Arizona $167M AUM 18.62% 1-Year Est. Return

WFG Advisors's PBE Position: Q2 2017 in Review

WFG Advisors held its Invesco Biotechnology & Genome ETF (PBE) position steady in Q2 2017 at 450 shares worth $21K. The position accounts for ﹤0.01% of the portfolio, ranked #949.

WFG Advisors first reported a position in PBE in Q2 2013 and has held it in 17 quarters since. The position peaked at $1.31M in Q1 2014. 64 funds tracked by Wall St. Rank hold PBE as of Q2 2017.

WFG Advisors held 450 shares of Invesco Biotechnology & Genome ETF worth $21K as of Q2 2017.
WFG Advisors left its Invesco Biotechnology & Genome ETF share count unchanged in Q2 2017.
Invesco Biotechnology & Genome ETF made up ﹤0.01% of WFG Advisors's portfolio in Q2 2017, its #949 holding.
WFG Advisors first reported a position in Invesco Biotechnology & Genome ETF in Q2 2013 and has held it in 17 quarters since.
WFG Advisors's Invesco Biotechnology & Genome ETF position peaked at $1.31M in Q1 2014.
64 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q2 2017.

Based on WFG Advisors's 13F filing for Q2 2017, filed 18 Aug 2017.